Adrian Rawcliffe, Adaptimmune CEO

#AS­CO21: Adap­ti­m­mune gives first glimpse at piv­otal da­ta for what they hope will be first ap­proved TCR

Six years af­ter Adap­ti­m­mune hauled what at the time was one of biotech’s largest-ever IPOs, CEO Adri­an Raw­cliffe thinks they’re fi­nal­ly on track to get the first TCR ther­a­py over the fin­ish line.

Adap­ti­m­mune re­leased new da­ta Wednes­day show­ing their TCR ther­a­py, known as afa­mi-cel, shrunk the tu­mors of 13 of the 33 evalu­able sec­ond-line sar­co­ma pa­tients, in­clud­ing two pa­tients whose tu­mors melt­ed en­tire­ly. That was good for a 39% ob­jec­tive re­sponse rate — which Raw­cliffe char­ac­ter­ized as a ma­jor ad­vance. He con­trast­ed it with the hand­ful of oth­er treat­ments avail­able for these pa­tients, such as Votri­ent, a chemother­a­py with a re­sponse rate in the sin­gle dig­its or low teens.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.